Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial

Journal of Thoracic and Cardiovascular Surgery

Volumn 136, Issue 6, 2008, Pages 1541-1548

  Mannacio, Vito A ^a   Iorio, Domenico ^a   De Amicis, Vincenzo ^a   Di Lello, Francesco ^a   Musumeci, F ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; MYOGLOBIN; PLACEBO; ROSUVASTATIN; TROPONIN I;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIUM; PREOPERATIVE CARE; PYRIMIDINES; SULFONAMIDES;

EID: 57949087269     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.06.038     Document Type: Article

References (40)

1. Noora J., Ricci C., Hasting D., and Hill S. Cybulsky. Determination of troponin release after CABG surgery. J Card Surg 20 (2005) 129-135
2. Sadony V., Korber M., Albes G., Podtschaske V., Etgen T., Trosken T., et al. Cardiac troponin I levels for diagnosis and quantization of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 13 (1998) 57-65
3. Etievent J.P., Chocron S., Toubin G., Taberlet C., Alwan K., Clement F., et al. Troponin I as a marker of perioperative myocardial ischemia. Ann Thorac Surg 59 (1995) 1192-1194
4. Jacquet L., Noirhomme P., El Khoury G., Goenen M., Philippe M., and Col J. Cardiac troponin I as early marker of myocardial damage after coronary artery bypass surgery. Eur J Cardiothorac Surg 13 (1998) 378-384
5. Horvath K.A., Parker M.A., Frederiksen J.W., Palmer A.S., and Fullerton D.A. Postoperative troponin I values: insult or injury?. Clin Cardiol 32 (2000) 731-735
6. Abramov D., Talilakh M.A., Frieger M., Ganiel A., Tuvbin D., and Wolak A. Plasma troponin level after cardiac surgery vs after myocardial infarction. Asian Cardiovasc Thorac Ann 14 (2006) 530-535
7. Botha P., Nagaraja D.P., Lewis P.S., and Dunning J. Can cardiac troponins be used to diagnose a perioperative myocardial infarction after cardiac surgery?. Interact Cardiovasc Thorac Surg 3 (2004) 442-449
8. Alexander J.H., Sparapani R.A., Mahaffey K.W., Deckers J.W., Newby L.H., Ohman E.M., et al. Association between minor elevation of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA 283 (2000) 347-353
9. Onorati F., De Feo M., Mastroroberto P., Cristodoro L., Pezzo F., Renzulli A., et al. Determinants and prognosis of myocardial damage after coronary artery bypass grafting. Ann Thorac Surg 79 (2005) 837-845
10. Yeh E.T.H., Anderson H.V., Pasceri V., and Willerson T. C reactive protein: linking inflammation to cardiovascular complications. Circulation 104 (2001) 974-975
11. Libby P. Molecular bases of acute coronary syndromes. Circulation 91 (1995) 2844-2850
12. Du Clos T.W. Function of C-reactive protein. Ann Med 32 (2000) 274-278
13. Pasceri V., Chang J., Willerson J.T., and Yeh E.T.H.I. Modulation of C reactive protein-mediated monocyte chemoattractant protein 1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
14. Lazar H.L., Bao Y., Zhang Y., and Bernard S.A. Pretreatment with statins enhance myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 125 (2003) 1037-1042
15. Clark L.L., Ikonomidis J.S., Crawford F.A., Crumbley A., Kratz J.M., and Stroud M.R. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg 131 (2006) 679-685
16. Kleeman R., Princen H.M.G., Emeis J.J., Jukema W., Fontijn R.D., Horrevoets A.J.G., et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE 3-Liden transgenic mice. Circulation 108 (2003) 1368-1374
17. Wilson S.H., Simari R.D., Best P.G., Peterson T.E., Lerman L.O., Aviram R., et al. Sinvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscer Thromb Vasc Biol 21 (2001) 122-128
18. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braumwald E. Long term effect of pravastatin on plasma concentration of C-reactive protein: the Cholesterol And Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
19. Resch U., Tatzeber F., Budinsky A., and Senzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61 (2006) 262-274
20. Jones S., Gibson M., Rimmer D., Gibson T., Sharp B., and Lefer D. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
21. Beishuizen E.D., Tamsma J.T., Jukama J.W., Van de Ree M., Van der Vijver J.C.M., Meinders A.E., et al. The effect of statin therapy and endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 28 (2005) 1668-1674
22. Schalkwisk C.G., Poland D.C.W., Van Dijk W., Kok A., Emeis J.J., Drager A.M., et al. Plasma concentration of C-reactive protein increases in type I diabetic patients without clinical microangiopathy and correlated with markers of endothelial dysfunction: evidence of chronic inflammation. Diabetologia 42 (1999) 351-357
23. Schinkel A.F., Poldermans D., Rizzallo V., Vanoverscheld J.L., Elhendy A., Boersma E., et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?. J Thorac Cardiovasc Surg 127 (2004) 385-390
24. Alpert J.S., Thygensen K., Antman E., and Bassand J.P. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
25. Benoit M.O., Paris M., Silleran J., Fiemejer A., and Moatti N. Cardiac troponin I: its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Thorac Cardiovasc Surg 49 (2001) 137-143
26. Fellahi J.L., Gue X., Richomme X., Monier M., Guillou L., and Riou B. Short and long term prognostic value of troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology 99 (2003) 270-274
27. Jarvinen O., Julkunes J., Saarinen S., Laurikka J., Huhtala H., and Tarkka M.R. Perioperative myocardial infarction has negative impact on health-related quality of life following coronary artery bypass graft surgery. Eur J Cardiothorac Surg 26 (2004) 621-627
28. Onorati F., Cristodoro L., Caroleo S., Esposito A., Amantea B., Santangelo E., et al. Troponin I and lactate for coronary sinus predict cardiac complications after myocardial revascularization. Ann Thorac Surg 83 (2007) 1016-1023
29. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., and Di Sciascio G. Randomized trial on atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 110 (2004) 674-678
30. Greenson N., Macoviak J., Krishnaswamy P., Morrisey R., James C., Clopton P., et al. Usefulness of cardiac troponin I in patients undergoing open heart surgery. Am Heart J 141 (2001) 447-455
31. Bonnefoy E., Filley S., Kirkorian G., Guidollet J., Roriz R., Robin J., et al. Troponin I, troponin T, or creatine kinase-MB to detect perioperative myocardial damage after coronary artery bypass surgery. Chest 114 (1998) 482-486
32. Drexler H., and Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 31 (1999) 51-60
33. Pesic S., Radenkovic M., and Grbovic L. Endothelial dysfunction: mechanism of development and therapeutic options. Med Pregl 59 (2006) 335-341
34. Politarchou C., and Papadimitriou E. Antioxidants inhibit human endothelial cell functions through down regulation of endothelial nitric oxide synthetase. Eur J Pharmacol 510 (2005) 31-38
35. Bulhak A.A., Gourine A.V., Gonon A.T., Sjoquist P.O., Valen G., and Pernow J. Oral pretreatment with rosuvastatin protects porcine myocardium from ischemia/reperfusion injury via a mechanism related to nitric oxide but no serum cholesterol level. Acta Physiol Scand 183 (2005) 151-159
36. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
37. Chello M., Mastroroberto P., Patti G., D'Ambrosio A., Morichetti M.C., Di Sciascio G., et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularization with cardiopulmonary bypass. Heart 89 (2003) 538-543
38. Engelman M.D.M., and Svendsen J.H. Inflammation in genesis and perpetual of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092
39. Lertsburapa K., While C.M., Kluger J., Faheem O., Hammonds J., and Coleman C.I. Preoperative statin therapy for prevention of atrial fibrillation after thoracic surgery. J Thorac Cardiovasc Surg 135 (2008) 405-411
40. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., Fukatsu A., Funami J., Ding Q.F., et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A 103 (2006) 17018-17023